Related Experiment Videos

The role of long-acting bronchodilators in the management of stable COPD

Donald P Tashkin1, Christopher B Cooper

  • 1Division of Pulmonary and Critical Care Medicine and the UCLA Pulmonary Function and Exercise Physiology Laboratory, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-1690, USA. DTashkin@mednet.ucla.edu

Chest
|January 14, 2004
PubMed

Insights

Long-acting bronchodilators effectively improve lung function in COPD patients. However, tiotropium consistently outperformed ipratropium, while salmeterol showed inconsistent results in preventing exacerbations and improving health status.

Area of Science:

  • Pulmonology
  • Pharmacology
  • Clinical Trials

Background:

  • Bronchodilators are foundational for symptomatic treatment of Chronic Obstructive Pulmonary Disease (COPD).
  • Large-scale efficacy studies of long-acting bronchodilators (LABDs) often postdate major clinical guidelines.
  • The Global Initiative for Chronic Obstructive Lung Disease (GOLD) provides treatment objectives for COPD.

Purpose of the Study:

  • To critically review large (> or =50 patients), double-blind clinical trials of tiotropium, formoterol, and salmeterol in COPD.
  • To evaluate the efficacy of these LABDs within the context of GOLD guidelines.
  • To propose a treatment algorithm for introducing LABDs in COPD management.

Main Methods:

  • Systematic review of published large-scale, double-blind clinical trials of tiotropium, formoterol, and salmeterol.
  • Studies were assessed for efficacy in improving lung function and other relevant COPD outcomes.
  • Comparison of findings against GOLD treatment objectives.

Main Results:

  • All three LABDs (tiotropium, formoterol, salmeterol) demonstrated effective improvement in lung function.
  • Tiotropium consistently showed superiority over short-acting ipratropium.
  • Salmeterol exhibited inconsistent efficacy in preventing exacerbations and improving health status compared to placebo.

Conclusions:

  • LABDs are effective for improving lung function in COPD patients.
  • Tiotropium offers consistent benefits beyond bronchodilation, unlike salmeterol.
  • A treatment algorithm recommending early introduction of LABDs for COPD is proposed.

Related Concept Videos

COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Inhaled Medications01:23

Inhaled Medications

Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
Chronic Obstructive Pulmonary Disease01:24

Chronic Obstructive Pulmonary Disease

COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...